Scope: The scope of the guideline is to provide clinical recommendations on the active surveillance of patients with prostate cancer. Any other treatment was considered to be out of scope.
Summary of National Clinical Guideline
This National Clinical Guideline contains evidence-based recommendations.
This guideline is for patients diagnosed with prostate cancer whose cancer may be suitable for “active surveillance”. Active surveillance is where you watch patient’s cancer closely and only start treatment if test results show it is getting worse. The document explains which patients’ prostate cancer can be managed with active surveillance. It also outlines the tests used to monitor the cancer during active surveillance and how often to get the tests.
It covers:
which patients are suitable for active surveillance enrolment
what type of tests should be included on an active surveillance protocol
how often should patients receive each test on an active surveillance protocol
when should a patient switch from active surveillance to a different treatment
The document also describes the changes in test results that may lead to switching to a different treatment. Ask your doctor or any member of your treating team if you want to know about your test results or treatment options.
Lynch Syndrome Ireland 